glyxambi
boehringer ingelheim international gmbh - empagliflozin, linagliptin - diabetes mellitus, typ 2 - lieky používané pri cukrovke - glyxambi, stabilnej dávke kombinácia empagliflozin a linagliptin, je indikovaný u dospelých vo veku 18 rokov a starších s diabetes mellitus 2. typu:ak chcete zvýšiť glykemický kontrolu pri metformínom a/alebo sulfonylmocoviny (su) a jeden z monocomponents z glyxambi neposkytujú dostatočnú glykemický kontroly;keď už liečená zadarmo zmes empagliflozin a linagliptin.
invokana
janssen-cilag international nv - canagliflozin - diabetes mellitus, typ 2 - lieky používané pri cukrovke - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5.
jardiance
boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - lieky používané pri cukrovke - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.
qtern
astra zeneca ab - saxagliptin, dapagliflozin propanediol monohydrát - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - lieky používané pri cukrovke - qtern, stabilnej dávke kombinácia saxagliptin a dapagliflozin, je indikovaný u dospelých vo veku 18 rokov a starších s diabetes mellitus 2. typu:ak chcete zvýšiť glykemický kontrolu pri metformínom a/alebo sulfonylmocoviny (su) a jeden z monocomponents z qtern neposkytujú dostatočnú glykemický kontroly,keď už liečená zadarmo zmes dapagliflozin a saxagliptin. (pozri časť 4. 2, 4. 4, 4. 5 a 5. 1 na dostupné údaje o kombinácie študoval.
alpivab
biocryst - peramivir - chrípka, človek - antivirotiká na systémové použitie - alpivab je indikovaný na liečbu nekomplikovanej chrípky u dospelých a detí od veku 2 rokov.
formovent 12 µg
itc farma s.r.l, taliansko - formoterol - 14 - bronchodilatantia, antiasthmatica
ventilastin novolizer
mylan ire healthcare limited, Írsko - salbutamol - 14 - bronchodilatantia, antiasthmatica
amglidia
ammtek - glibenclamide - cukrovka - lieky používané pri cukrovke - amglidia je indikovaný na liečbu novorodeneckého diabetu mellitus, pre použitie u novorodencov, dojčiat a detí. sulphonylureas ako amglidia sa ukázali byť účinné u pacientov s mutáciami v génoch kódovanie pre β-buniek atp-citlivé draslík kanál a chromozómové 6q24 súvisiace s prechodným novorodeneckého diabetu mellitus.
formostad 12 mikrogramov inhalačný prášok v tvrdej kapsule
stada arzneimittel ag, nemecko - formoterol - 14 - bronchodilatantia, antiasthmatica
dapagliflozin viatris
viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lieky používané pri cukrovke - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.